Investors focused on the Medical space have likely heard of Applied Genetic Technologies (AGTC - Free Report) , but is the stock performing well in comparison to the rest of its sector peers? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
Applied Genetic Technologies is a member of our Medical group, which includes 844 different companies and currently sits at #2 in the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. AGTC is currently sporting a Zacks Rank of #1 (Strong Buy).
Over the past 90 days, the Zacks Consensus Estimate for AGTC's full-year earnings has moved 100.53% higher. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, AGTC has returned 53.01% so far this year. Meanwhile, the Medical sector has returned an average of 5.79% on a year-to-date basis. This means that Applied Genetic Technologies is performing better than its sector in terms of year-to-date returns.
Breaking things down more, AGTC is a member of the Medical - Biomedical and Genetics industry, which includes 352 individual companies and currently sits at #73 in the Zacks Industry Rank. On average, this group has gained an average of 2.30% so far this year, meaning that AGTC is performing better in terms of year-to-date returns.
Investors with an interest in Medical stocks should continue to track AGTC. The stock will be looking to continue its solid performance.